title: Evaluation of Cell-Free Urine microRNAs Expression for the Use in Diagnosis of Ovarian and Endometrial Cancers. A Pilot Study.
abstract: Among gynaecological cancers, epithelial ovarian cancers are the most deadly cancers while endometrial cancers are the most common diseases. Efforts to establish relevant novel diagnostic, screening and prognostic markers are aimed to help reduce the high level of mortality, chemoresistance and recurrence, particularly in ovarian cancer. MicroRNAs, the class of post-transcriptional regulators, have emerged as the promising diagnostic and prognostic markers associated with various diseased states recently. Urine has been shown as the source of microRNAs several years ago; however, there has been lack of information on urine microRNA expression in ovarian and endometrial cancers till now. In this pilot study, we examined the expression of candidate cell-free urine microRNAs in ovarian cancer and endometrial cancer patients using quantitative real-time PCR. We compared the expression between pre- and post-surgery ovarian cancer samples, and between patients with ovarian and endometrial cancers and healthy controls, within three types of experiments. These experiments evaluated three different isolation methods of urine RNA, representing two supernatant and one exosome fractions of extracellular microRNA. In ovarian cancer, we found miR-92a significantly up-regulated, and miR-106b significantly down-regulated in comparison with control samples. In endometrial cancer, only miR-106b was found down-regulated significantly compared to control samples. Using exosome RNA, no significant de-regulations in microRNAs expression could be found in either of the cancers investigated. We propose that more research should now focus on confirming the diagnostic potential of urine microRNAs in gynaecological cancers using more clinical samples and large-scale expression profiling methods.
authors.affiliation: Institute of Biology and Medical Genetics, the First Faculty of Medicine, Charles University Prague and General University Hospital in Prague, Albertov 4, CZ-128 00, Prague 2, the Czech Republic, ludek.zavesky@gmail.com.
authors.forename: Luděk
authors.initials: L
authors.lastname: Záveský
authors.forename: Eva
authors.initials: E
authors.lastname: Jandáková
authors.forename: Radovan
authors.initials: R
authors.lastname: Turyna
authors.forename: Lucie
authors.initials: L
authors.lastname: Langmeierová
authors.forename: Vít
authors.initials: V
authors.lastname: Weinberger
authors.forename: Lenka
authors.initials: L
authors.lastname: Záveská Drábková
authors.forename: Martina
authors.initials: M
authors.lastname: Hůlková
authors.forename: Aleš
authors.initials: A
authors.lastname: Hořínek
authors.forename: Daniela
authors.initials: D
authors.lastname: Dušková
authors.forename: Jaroslav
authors.initials: J
authors.lastname: Feyereisl
authors.forename: Luboš
authors.initials: L
authors.lastname: Minář
authors.forename: Milada
authors.initials: M
authors.lastname: Kohoutová
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000235:genetics / Q000652:urine; D016022:Case-Control Studies; D015536:Down-Regulation / Q000235:genetics; D016889:Endometrial Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000652:urine*; D055354:Exosomes / Q000235:genetics; D005260:Female; D006801:Humans; D035683:MicroRNAs / Q000235:genetics* / Q000652:urine*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000652:urine*; D010865:Pilot Projects; D011379:Prognosis; D015854:Up-Regulation / Q000235:genetics
chemical_list: D014408:Biomarkers, Tumor; D035683:MicroRNAs
references.citation: Oncol Rep. 2011 Oct;26(4):995-1002
references.pmid: 21725615
references.citation: PLoS One. 2009;4(4):e5311
references.pmid: 19390579
references.citation: Cancer Sci. 2014 Jan;105(1):18-25
references.pmid: 24164962
references.citation: BMC Cancer. 2012 Dec 28;12:627
references.pmid: 23272653
references.citation: J Cancer. 2014 Jan 29;5(3):182-91
references.pmid: 24563673
references.citation: Cancer Sci. 2010 Jan;101(1):241-9
references.pmid: 19891660
references.citation: Cancer Sci. 2011 Mar;102(3):522-9
references.pmid: 21166959
references.citation: Urol Oncol. 2010 Nov-Dec;28(6):655-61
references.pmid: 19375957
references.citation: Neoplasma. 2011;58(6):457-68
references.pmid: 21895398
references.citation: Br J Cancer. 2012 Feb 14;106(4):768-74
references.pmid: 22240788
references.citation: BMC Bioinformatics. 2008 Jul 30;9:326
references.pmid: 18667053
references.citation: Exp Hematol Oncol. 2014 May 20;3:14
references.pmid: 24910811
references.citation: EMBO Mol Med. 2012 Mar;4(3):143-59
references.pmid: 22351564
references.citation: Biotechnol Lett. 2004 Mar;26(6):509-15
references.pmid: 15127793
references.citation: Gynecol Oncol. 2009 Jan;112(1):55-9
references.pmid: 18954897
references.citation: Br J Cancer. 2014 Feb 18;110(4):976-83
references.pmid: 24366298
references.citation: Clin Genitourin Cancer. 2012 Jun;10 (2):106-13
references.pmid: 22386240
references.citation: Clin Chem. 2010 Nov;56(11):1733-41
references.pmid: 20847327
references.citation: PLoS One. 2008 Jun 18;3(6):e2436
references.pmid: 18560586
references.citation: Int J Cancer. 2013 Dec 1;133(11):2631-41
references.pmid: 23686449
references.citation: Mol Cancer. 2008 Apr 28;7:35
references.pmid: 18442408
references.citation: CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
references.pmid: 24399786
references.citation: Cancer Res. 2004 Aug 1;64(15):5245-50
references.pmid: 15289330
references.citation: Mol Carcinog. 2014 May;53(5):349-59
references.pmid: 24002805
references.citation: J Comput Biol. 2005 Oct;12(8):1047-64
references.pmid: 16241897
references.citation: Br J Cancer. 2010 Aug 24;103(5):693-700
references.pmid: 20683447
references.citation: Int J Mol Sci. 2013 Jun 06;14(6):12123-37
references.pmid: 23743825